The ITFG2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatic adenocarcinoma line, featuring targeted disruption of the ITFG2 gene. This loss-of-function model enables precise dissection of ITFG2 functions in a liver cancer context, providing a valuable tool for studies on integrin-mediated signaling, cell migration, and metastatic progression. The polyclonal nature of the knockout pool reflects a heterogeneous mix of edited alleles, making it suitable for population-level analyses of gene disruption effects without clonal selection artifacts.
SK-HEP-1 cells are an ascites-derived, adherent epithelial cell line originating from a liver adenocarcinoma patient and are widely employed as a model for hepatocellular carcinoma and metastatic liver cancer. These cells exhibit robust migratory and invasive properties, in part driven by active integrin signaling pathways. Their mesenchymal-like phenotype and ability to form tumors in xenograft models render them an appropriate host background for investigating genes implicated in the metastasis cascade, including those that regulate adhesion dynamics and cytoskeletal remodeling.
ITFG2 encodes an integrin ?? FG-GAP repeat-containing protein that functions as a key modulator of integrin-dependent cell adhesion and motility. Mechanistically, ITFG2 interacts directly with integrin ??1 (ITGB1) and forms complexes with integrin ??5 (ITGA5) to promote the assembly and maturation of focal adhesions. This event triggers the recruitment and phosphorylation of focal adhesion kinase (FAK) and SRC family kinases, which subsequently activate downstream effectors including AKT, RAC1, and RHOA. As a result, ITFG2 integrates signals from extracellular matrix ligands such as fibronectin and collagen I, as well as from soluble factors like TGF-??, to drive actin cytoskeleton reorganization via proteins like talin (TLN), paxillin (PXN), vinculin (VCL), and ??-actin (ACTB). Through this signaling axis, ITFG2 links integrin engagement to PI3K-AKT signaling, ultimately promoting directed cell migration and invasion.
In the SK-HEP-1 adenocarcinoma background, loss of ITFG2 is expected to disrupt focal adhesion dynamics and impair the ability of these cells to migrate and invade through extracellular matrix barriers, which are critical steps in hepatocellular carcinoma dissemination. This model thus provides a physiologically relevant system for examining how ITFG2-dependent integrin signaling sustains the metastatic phenotype of liver cancer cells. Moreover, it facilitates the study of ITFG2 as a potential target for therapeutic intervention aimed at blocking liver adenocarcinoma progression and metastasis.
This knockout product is well suited for a range of experimental applications, including cancer metastasis research, integrin signal transduction analysis, and liver cancer biology investigations. Typical assays include wound healing migration assays, Transwell invasion assays, western blotting of key phospho-proteins such as FAK and AKT, immunofluorescence visualization of focal adhesion structures, co-immunoprecipitation of ITGB1 complexes, and flow cytometric assessments of integrin surface expression. It can additionally be used in drug screening campaigns to identify compounds that perturb ITFG2-mediated invasive signaling. For more detailed information or technical support, please contact Ascent Research.
